Skylar Jeremias

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, shares his thoughts on long COVID-19 among those with type 2 diabetes and the rise of new-onset cases of type 1 diabetes throughout the pandemic.

Adding risk factors specific to patients with chronic kidney disease (CKD) to risk prediction models for cardiovascular disease (CVD) could improve risk prediction capabilities for a population of patients often subject to invasive diagnostic procedures, investigators concluded.

Megan Olsen, MPH, principal at Avalere, explains how payers are attempting to get around cost concerns associated with expensive cell and gene therapies.

Researchers concluded that incident corneal adverse events in patients with multiple myeloma (MM) carry a low clinical and economic burden compared with total all-cause costs and MM-related per-patient-per-month costs.

Patients with multiple myeloma (MM) who have been fully vaccinated against COVID-19 were found to have an increased risk of breakthrough infections and related hospitalizations, signaling the need for more studies and precautions.

Patients with chronic kidney disease (CKD) and their caregivers who have participated in CKD research shared factors that may encourage or discourage others from enrolling in clinical studies, highlighting the ways that investigators can better involve patients in research.

Megan Olsen, MPH, principal at Avalere, explores the challenges that arise for Medicaid plans when providers choose to prescribe a cell or gene therapy.

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, talks about how biosimilars have been able to help patients avoid financial toxicity related to oncology care costs.

Robert Gabbay, MD, PhD, of the American Diabetes Association (ADA), discusses the development process for the section of ADA guidelines that touches on chronic kidney disease (CKD) management in patients with diabetes.

Early mortality rates for patients with multiple myeloma (MM) have significantly decreased over the last 20 years; however, more efforts are needed for older patients, who still experience high rates.

Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses some of the challenges of treating pediatric patients with type 1 or type 2 diabetes.

A large international real-world analysis revealed the extent to which the COVID-19 pandemic has impacted the global population of patients with multiple myeloma (MM) and the ability for providers to help patients manage the condition.

About half of all patients with multiple myeloma (MM) receiving corticosteroid-based chemotherapy were found to have adrenal insufficiency (AI), while identifying suspicious symptoms of AI may be a key component to its detection in this population.

Megan Olsen, MPH, principal at Avalere, provides a comprehensive overlook into the many ways that the COVID-19 pandemic has impacted the cell and gene therapy space.

The American Diabetes Association (ADA) has added a new section to their 2022 Standard of Care guidelines to assist clinicians in managing and preventing the presence of chronic kidney disease and related complications in patients with diabetes.

Study results showed that both the Pfizer-BioNTech and Moderna COVID-19 vaccines were safe and effective in patients with multiple myeloma, which investigators hope will improve vaccine hesitancy in the high-risk population.

Payer intervention, lack of patient savings, and confusion surrounding interchangeability are some of the many barriers standing in the way of US biosimilar uptake, with our group of panelists calling for big changes.

Although men and women with advanced kidney disease experienced physical and mental declines in health-related quality of life (QOL), men’s declines occurred at a significantly faster rate, researchers concluded.

Researchers have found that most US patent infringement cases against biosimilar manufacturers cover patents filed over a decade after the originator product's FDA approval, leading to limits on competition among biologic drugs.

More nutritional care may be needed for elderly patients with chronic kidney disease (CKD) who are ingesting higher-than-recommended amounts of protein, investigators concluded.

A study comparing 4 different artificial intelligence (AI) models found that some models were better than others at detecting early-stage chronic kidney disease (CKD), when patients do not experience visible symptoms.

Prior to receiving therapy for non–small cell lung cancer (NSCLC), some patients' results may require analysis beyond comprehensive genomic profiling (CGP).

Older patients with Parkinson disease (PD) were found to have a higher incidence of dementia compared with younger patients. However, the difference may have to do with different pathologies causing dementia in older and younger patients.

More biobetter drugs may be on the horizon, with an opportunity to snatch market share from reference products, and several biosimilars are under development for ophthalmic conditions, authors of a review concluded.

Investigators offered insight into disparities between countries regarding chronic kidney disease burden and suggestions on how those disparities can be addressed.

Posters from the Academy of Managed Care Pharmacy Nexus 2021 meeting detailed how coverage of genetic testing aligns with current guidelines as well as the potential budget impact of expanding access to comprehensive genomic profiling (CGP).

Risk of recurrent venous thromboembolism (VTE) in patients with chronic kidney disease (CKD) and VTE was significantly reduced in those who were treated with apixaban vs warfarin, investigators concluded.

Video games that involve physical exertion was found to be more effective at improving balance in patients with multiple sclerosis (MS) compared with more conventional rehabilitation methods, investigators concluded.

Insulin resistance may become a future target of treatment in the chronic kidney disease (CKD) population because of the several mechanisms in patients that contribute to increasing resistance, authors of a review concluded.

A review of published literature revealed which diet methods and forms of physical activity are most effective at improving patient-reported outcomes in patients with multiple sclerosis (MS).